Immunization of six-month-old infants with different doses of edmonston⇓zagreb and schwarz measles vaccines

New England Journal of Medicine

Volumn 322, Issue 9, 1990, Pages 580-587

  Markowitz, Lauri E ^a   Zell, Elizabeth R ^a   Bernier, Roger H ^a   Sepulveda, Jaime ^b   Diaz Ortega, Jose Luis ^b   Valdespino, Jose Luis ^b   Albrecht, Paul ^c   Stewart, John ^a   Zarate, Maria Luisa ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ministry of Health   (Mexico)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

AGE; ARTICLE; HUMAN; INFANT; MEASLES; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SUBCUTANEOUS DRUG ADMINISTRATION;

AGE FACTORS; ANTIBODIES, VIRAL; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMAN; INFANT; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RANDOM ALLOCATION; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; VACCINATION;

EID: 0025315066     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199003013220903     Document Type: Article

References (47)

1. Henderson RH, Keja J, Hayden G, Galazka A, Clements J, Chan C. Immunizing the children of the world: progress and prospects. Bull WHO 1988; 66: 535–43.
2. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977; 91: 715–8.
3. Ministries of Health of Brazil, Chile, Costa Rica, Ecuador, Pan American Health Organization. Seroconversion rates and measles antibody titer induced by measles vaccine in Latin American children 6–12 months of age. Bull Pan Am Health Org 1982; 16: 272–85.
4. Ministry of Health of Kenya, World Health Organization. Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Bull WHO 1977; 55: 21–31.
5. World Health Organization. Expanded Programme on Immunization: the optimal age for measles immunization. Weekly Epidemiological Record. Vol. 57. March 26, 1982: 89–91.
6. Taylor WR, Mambu RK, Ma-Disu M, Weinman JM. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol 1988; 127: 788–94.
7. Aaby P. Malnutrition and overcrowding/intensive exposure in severe measles infection: review of community studies. Rev Infect Dis 1988; 10: 478–91.
8. Fernandez de Castro J. Measles in Mexico. Rev Infect Dis 1983; 5: 422–6.
9. Sabin AB, Flores Arechiga A, Fernández de Castro J, et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983; 249: 2651–62.
10. Sabin AB, Flores Arechiga A, Fernández de Castro J, Albrecht P, Sever JL, Shekarchi I. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984; 251: 2363–71.
11. Whittle HC, Rowland MG, Mann GF, Lamb WH, Lewis RA. Immunisation of 4–6 month old Gambian infants with Edmonston–Zagreb measles vaccine. Lancet 1984; 2: 834–7.
12. Beck M, Smerdel S, Dedic I, et al. Immune response to Edmonston–Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Stand 1986; 65: 95–100.
13. Whittle HC, Mann G, Eccles M, et al. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4–5 months. Lancet 1988; 1: 963–6.
14. Whittle H, Hanlon P, O'Neill K, et al. Trial of high-dose Edmonston–Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet 1988; 2: 811–4.
15. Khanum S, Uddin N, Garelick H, Mann G, Tomkins A. Comparison of Edmonston–Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987; 1: 150–3.
16. Fernández de Castro J, Valdespino Gómez JL, Diaz Ortega JL, Zárate Aquino L. Diploid cell measles vaccine. JAMA 1986; 256: 714.
17. Tidjani O, Grunitsky B, Guérin N, et al. Serological effects of Edmonston–Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4–5 or 8–10 months. Lancet 1989; 2: 1357–60.
18. Ikic D, Juzbasic M, Beck M, Hrabar A, Cimbur-Schreiber T. Attenuation and characterisation of Edmonston–Zagreb measles virus. Ann Immunol Hung 1972; 16: 175–81.
19. Sepulveda AJ, De Mucha MJ, Valdespino JL, Diaz Ortega JL. La cepa Edmonston–Zagreb de la vacuna antisaramparion. Gac Med Mex 1988; 124: 75–81.
20. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3: 251–60.
21. Sato H, Albrecht P, Reynolds DW, Stagno S, Ennis FA. Transfer of measles, mumps, and rubella antibodies from mother to infant: its effect on measles, mumps and rubella immunization. Am J Dis Child 1979; 133: 1240–3.
22. Chen R, Mofenson L, Albrecht P, Page P, Orenstein W, Etkind P. Protective measles antibody titers in college students. Presented at the 35th annual Epidemic Intelligence Service conference, Atlanta, April 14–18, 1986.
23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
24. Stanish WM. Categorical data analysis strategies using SAS software. In: Allen DM, ed. Computer science and statistics: proceedings of the 17th Symposium on the Interface, Lexington, Ky., March 1985. Amsterdam: Elsevier Science, 1986:239–56.
25. SAS Institute Inc. SAS/STAT™ guide for personal computers, version 6 ed. Cary, N.C.: SAS Institute, 1987.
26. Neter J, Wasserman W, Kutner MH. Applied linear statistical models: regression, analysis of variance, and experimental designs. 2nd ed. Homewood, Ill.: R.D. Irwin, 1985.
27. Schwarz AJF. Immunization against measles: development and evaluation of a highly attenuated live measles vaccine. Ann Paediatr 1964; 202: 241–52.
28. Mann GF. New approaches to the practical problems of measles vaccine. In: Proceedings of the symposium on stability and effectiveness of measles, poliomyelitis and pertussis vaccines. Zagreb: Yugoslav Academy of Sciences and Arts, 1976:73–9.
29. Mann GF, Allison LM, Copeland JA, Agostini CF, Zuckerman AJ. A simplified plaque assay system for measles virus. J Biol Stand 1980; 8: 219–25.
30. Calain P, Roux L. Generation of measles virus defective interfering particles and their presence in a preparation of attenuated live-virus vaccine. J Virol 1988; 62: 2859–66.
31. Meyer HM Jr, Bemheim BC, Rogers NG. Titration of live measles and smallpox vaccines by jet inoculation of susceptible children. Proc Soc Exp Biol Med 1965; 118: 53–7.
32. Rosenbloom AL, Taylor M, Casey HL. Attenuated measles virus vaccine dosage study in central Africa. J Trop Med Hyg 1970; 73: 183–5.
33. McCrumb FR Jr, Bulkeley JT, Hornick RB, Snyder MJ, Togo Y. Clinical trials with living attenuated measles virus vaccines. Am J Public Health 1962; 52: Suppl II: 11–5.
34. Landrigan PJ, Murphy KB, Meyer HM Jr, Parkman PD, Eddins DL, Witte JJ. Combined measles-rubella vaccines: virus dose and serologic response. Am J Dis Child 1973; 125: 65–7.
35. Hendrickse RG, Montefiore D. Measles vaccination with reduced dosage. Br Med J 1968; 3: 28–30.
36. Kempe CH, Ott EW, St. Vincent L, Maisel JC. Studies on an attenuated measles-virus vaccine. III. Clinical and antigenic effects of vaccine in institutionalized children. N Engl J Med 1960; 263: 162–5.
37. Buynak EB, Weibel RE, Whitman JE Jr, Stokes J Jr, Hilleman MR. Combined live measles, mumps, and rubella virus vaccines. JAMA 1969; 207: 2259–62.
38. Karelitz S, Desposito R, Gittelson S, et al. Measles vaccine. JAMA 1961; 177: 537–41.
39. Vesikari T, Ala-Laurila EL, Heikkinen A, Terho A, D'Hondt E, Andre FE. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. Am J Dis Child 1984; 138: 843–7.
40. Gendrel D, Garin D, Dutailly C, et al. Immunization of young infants with high doses of Schwartz measles vaccine. Pediatr Infect Dis J 1988; 7: 523–5.
41. Ueda S, Takahashi M, Minekawa Y, Ogino T, Suzuki N. Studies on further attenuated live measles vaccine. II. Correlation between the titer of the vaccine, the antibody response and clinical reactions. Biken J 1970; 13: 117–20.
42. Sabin AB, Albrecht P, Takeda AK, Ribeiro EM, Veronesi R. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in 7-month-old and older infants. J Infect Dis 1985; 152: 1231–7.
43. Wallace RB, Landrigan PJ, Smith EA, Pifer J, Teller B, Foster SO. Trial of a reduced dose of measles vaccine in Nigerian children. Bull WHO 1976; 53: 361–4.
44. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr 1965; 66: 471–88.
45. Mathias RG, Meeklson WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989; 79: 475–8.
46. Black FL, Berman LL, Borgono JM, et al. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986; 124: 442–52.
47. Black FL, Berman LL, Libel M, et al. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull WHO 1984; 62: 315–9.